title: Diabetes 2030: Insights from Yesterday, Today, and Future Trends.
abstract: To forecast future trends in diabetes prevalence, morbidity, and costs in the United States, the Institute for Alternative Futures has updated its diabetes forecasting model and extended its projections to 2030 for the nation, all states, and several metropolitan areas. This paper describes the methodology and data sources for these diabetes forecasts and discusses key implications. In short, diabetes will remain a major health crisis in America, in spite of medical advances and prevention efforts. The prevalence of diabetes (type 2 diabetes and type 1 diabetes) will increase by 54% to more than 54.9 million Americans between 2015 and 2030; annual deaths attributed to diabetes will climb by 38% to 385,800; and total annual medical and societal costs related to diabetes will increase 53% to more than $622 billion by 2030. Improvements in management reducing the annual incidence of morbidities and premature deaths related to diabetes over this time period will result in diabetes patients living longer, but requiring many years of comprehensive management of multiple chronic diseases, resulting in dramatically increased costs. Aggressive population health measures, including increased availability of diabetes prevention programs, could help millions of adults prevent or delay the progression to type 2 diabetes, thereby helping turn around these dire projections.
authors.affiliation: 1 Institute for Alternative Futures , Alexandria, Virginia.
authors.forename: William R
authors.initials: WR
authors.lastname: Rowley
authors.affiliation: 1 Institute for Alternative Futures , Alexandria, Virginia.
authors.forename: Clement
authors.initials: C
authors.lastname: Bezold
authors.affiliation: 1 Institute for Alternative Futures , Alexandria, Virginia.
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Arikan
authors.affiliation: 2 Public Affairs Strategy, Novo Nordisk Inc. , Plainsboro, New Jersey.
authors.forename: Erin
authors.initials: E
authors.lastname: Byrne
authors.affiliation: 3 Novo Nordisk Inc. , Washington, District of Columbia.
authors.forename: Shannon
authors.initials: S
authors.lastname: Krohe
mesh_terms: D000328:Adult; D000368:Aged; D002487:Centers for Disease Control and Prevention, U.S.; D016208:Databases, Factual; D003922:Diabetes Mellitus, Type 1 / Q000191:economics / Q000453:epidemiology* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000191:economics / Q000453:epidemiology* / Q000503:physiopathology; D005260:Female; D062305:Geographic Mapping; D017048:Health Care Costs / Q000639:trends; D006801:Humans; D008297:Male; D008875:Middle Aged; D009017:Morbidity / Q000639:trends; D009026:Mortality / Q000639:trends; D015995:Prevalence; D014481:United States / Q000453:epidemiology; D055815:Young Adult